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Abstract: Several authors have recently claimed an excess 
in serum folate test ordering, suggesting phasing out 
it from clinical use. According to studies performed in 
countries undergoing folic acid fortification policies, it 
is indeed no more cost-effective to test folate in the face 
of deficiency prevalence < 1%. In this paper, we sought 
to evaluate request appropriateness, analytical issues, 
and cost-effectiveness of serum folate determination for 
clinical purposes in the European context, considering if 
evidence retrieved in fortified countries may be general-
ized. Studies performed in non-fortified countries have 
generally reported a suboptimal folate intake and suggest 
a remarkable prevalence of folate deficiency. Our internal 
data suggest that ~ 20%–25% of the subjects undergoing 
serum folate test are at risk for deficiency. However, a 
reliable evaluation of the risk for deficiency implies the 
knowledge of all issues related to the total testing pro-
cess of folate measurement as well as the identification 
of the appropriate population in which to perform the 
test. The cost-effectiveness of the test is maximized when 
the request is oriented to subjects suggestive/at risk for 
deficiency, becoming low if the test is used as a screen-
ing tool or for monitoring of vitamin intake/supplementa-
tion. Because the individual folate status has a key role 
in ensuring normal development, physiologic growth, 
and maintenance of optimal health, the evaluation of 
its serum levels has to be retained in the clinical use in 
 non-fortified countries, boosting for more appropriate 
request, and evidence from countries following fortifica-
tion policies should be cautionary interpreted.
Keywords: assay; biological variability; folate; request; 
traceability.
Introduction
Recently, several authors have debated the utility of serum 
folate testing, also in face of the high rate of misuse and of 
the associated costs [1–5]. From the retrospective analysis 
of data, a shared position on the utility and cost-effective-
ness of folate testing has emerged. The main evidence is 
well summarized in the systematic review by the Canadian 
Agency for Drugs and Technologies in Health (CADTH) [6], 
showing that the folate test is highly requested, but its 
results do not affect the clinical management of patients, 
thus resulting in a poor cost-effectiveness [7–9]. The 
CADTH report is well rooted on the evidence mainly built 
on American/Australian populations, characterized by a 
far low prevalence of folate deficiency (ranging from 0.1 to 
1%) due to wheat flour folate fortification [6, 10, 11]. Nev-
ertheless, appraisals claim that the rate of folate testing 
has not significantly changed after fortification to yield a 
significant shrinkage of costs, although indications for the 
appropriateness of the request have been clearly reported 
[6, 12].
Although folate testing in subjects without known 
risk factors has little clinical significance [13], a wide 
range of conditions have been identified all potentially 
impairing folate intake/absorption or increasing require-
ment (Table 1) [5, 6, 14–17]. For many of these risk condi-
tions, a poor clinical utility of folate testing has, however, 
been reported, since patients usually exhibit serum 
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concentrations well within the reference interval, and this 
is true in non-fortified countries too [5, 18, 19].
Several US authors are now seeking for phase out 
folate testing according to the mentioned evidence of low 
utility and poor cost-effectiveness for both inpatients and 
outpatients [1, 4, 20]. It is also noteworthy that for several 
populations of individuals at risk for deficiency, folic acid 
supplementation is highly recommended or suggested, 
but folate testing is not required or is not accounted for 
prior initiating supplementation [8, 9]. Furthermore, it 
has been reported that the knowledge of low folate results 
often does not change the clinical management of patients 
[6]. This is fostered by the lack of evidence on the benefit 
associated to or consequent to folate testing [1, 6, 20]. On 
the other hand, it has been shown that the direct costs of 
folate testing overcome those of supplementation, which 
is not associated to side effects apart from masking hema-
tological symptoms of vitamin B12 deficiency with exacer-
bation of neurological symptoms [9].
In 2000, a European document focused on the toler-
able upper intake level of folate, alerting that the excess of 
synthetic folic acid supplementation may increase the con-
centration of unmetabolized folic acid (UMFA). The accu-
mulation of both vitamers may result in various adverse 
outcomes, such as epileptogenic and neurotoxic effects, 
decreased efficacy of some chemotherapeutics, decreased 
zinc absorption and deficiency, and carcinogenicity [21–
23]. More recently, other authors wholly disagreed with 
these warnings, observing that the relationship of folic 
acid with adverse effects can be affected by several con-
founding factors [24]. For instance, the hypothesis of an 
association of folic acid supplementation with cancer 
development is rapidly declining, owing to its possible 
chemopreventive role and no evidence of a relationship 
with cancer incidence [24, 25]. Currently, the main indica-
tion on a possible adverse effect of folic acid upper intake 
level addresses the surveillance of the elderly for what 
concerns the possible masking of a vitamin B12 deficit [21]. 
Any possible effect of blood UMFA on health remains to be 
elucidated, and this is not an easy task, considering that 
folate assays available for clinical purposes are not able to 
detect it [26].
Considering the above-described premise, it seems 
appropriate to review here the cost-effectiveness of serum 
folate determination for clinical purposes in the European 
context, considering if the evidence retrieved in countries 
undergoing mandatory folic acid fortification policy may 
be generalized to other countries and the related pipeline 
shared.
Folate testing to quote risk for 
 deficiency in Europe: a public 
health problem
Evidence from European countries
Although the CADTH report represents the most recent 
and exhaustive review on optimal methods for folate 
testing, its clinical utility, cost-effectiveness, and appro-
priateness of the request, in Europe, we cannot, in prin-
ciple, rely on recommendations built in folate-fortified 
countries. Here, the prevalence of folate deficiency is now 
too low to provide a reliable evidence on the clinical utility 
of this test. As for all tests used in laboratory medicine, the 
capability of folate results to correctly identify or exclude 
a deficiency strongly depends on the prevalence (pre-
test probability) of the condition in the clinical setting in 
which the test is applied [27].
A robust and updated estimate of folate deficiency in 
the European countries is lacking, although several docu-
ments have reported on the occurrence and incidence of 
diseases related to folate deficiency, with strong recom-
mendations on supplementation [28–31]. This concept has 
recently been reinforced by Mills and Dimopoulos, dis-
cussing on the possible introduction of folic acid fortifica-
tion in Europe and observing that the cost-benefit of this 
Table 1: Conditions potentially impairing folate intake/absorption 
or increasing requirement.
–  Inadequate intake (e.g. malnutrition, low intake of folate-rich or 
folic acid-fortified foods)
–  Impaired absorption (e.g. gastrointestinal disease, bariatric 
surgery patients, laparoscopic biliopancreatic diversion with or 
without duodenal switch, gastric by-pass, sleeve gastrectomy 
procedures, inflammatory bowel and Crohn’s disease, 
inflammation of small intestine due to coeliac disease, tropical 
sprue, use of drugs such as metformin, proton pump inhibitors, 
oral contraceptives, anticonvulsants, sulfasalazine, triamterene 
and pyrimethmine)
– Increased requirements (e.g. pregnancy and lactation)
– Lifestyle (e.g. alcohol abuse)
–  Genetic factors (mutations in the SLC46A1 gene, proton-coupled 
folate transporter deficiency)
–  Other clinical conditions associated to: evidence of anemia 
and/or macrocytosis, neuropsychiatric symptoms (depression, 
psychosis) or Alzheimer’s and non-Alzheimer’s dementia, poor 
proprioception, peripheral neuropathy, history of glossitis and 
mouth ulceration, autoimmune disease, chronic hemolytic 
states, chronic kidney disease and renal dialysis, malignancy 
(e.g. leukemia, non-myeloid malignancies at risk for anemia), 
situations similar to vitamin B12 deficiency
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policy in US has been shown by the consequent dropping 
of folate deficiency (from 24% to < 1%, according to the 
measurement of serum folate) [32, 33]. The perception that 
folate deficiency is quite disregarded in Europe emerges 
from the guidelines retrieved by the CADTH review: out 
of nine, only two have been developed in Europe, both 
by the European Federation of Neurological Societies [34, 
35]. Some speculations on a remarkable prevalence of 
folate deficiency may be gathered from national surveys 
reporting on the nutritional behaviour of the populations 
in European countries, although the direct measurement 
of serum folate has been performed only in ~ 40% of these 
studies [26, 28, 30]. Accordingly, it has been shown that 
in the Netherlands, Norway, Sweden, and Greece, the 
mean (± SD) serum folate concentrations [3.4 (± 0.3) μg/L] 
reflects a poor food-based folate intake, which could also 
be dependent on the way food manufacturers supplement 
their grain products [26]. A moderate intake [estimated by 
a mean (± SD) serum folate of 5.6 (± 0.8) μg/L] has been 
reported for Finland, Ireland, Czech, Italy, and Portugal, 
whereas favorable folate concentrations in serum (7.3 ± 0.6 
μg/L) have been detected in UK, Germany, and Spain [28].
In Italy, there are few updated evaluations on serum 
folate concentrations in the general population under 
healthy conditions. The first study, performed on blood 
donors, dates back to 2000 [36]. The mean folate concen-
tration for all case series (n = 201) was ~ 5.0 μg/L, with no 
sex-dependent differences. The rate of subjects below the 
adopted lower reference limit [i.e. 3.0 μg/L by Abbott Diag-
nostics microparticle enzyme immunoassay (MEIA)] was 
9.9%, with no gender dependence [36]. More recently, Zap-
pacosta et al. [37] evaluated serum folate concentrations 
in blood donors accrued in the middle-southern Italy. 
On a case series of 240 subjects, the overall mean folate 
concentration (Abbott MEIA) was 4.8 μg/L, with concen-
trations being slightly higher in women. From this study, 
we cannot estimate the percentage of subjects with folate 
deficiency, but, by defining adequate serum folate con-
centrations as > 6.6 μg/L, the authors observed that only 
22.5% of the study participants showed an adequate folate 
intake. Results from multiple logistic regression showed 
that female gender, older age, no smoking habit, regular 
physical activity, and consumption of at least three por-
tions of vegetable/fruits per day promoted higher folate 
concentrations [37]. Two further studies specifically 
focusing on the age dependence of folate concentrations 
in serum have reported that folate deficiency increases 
with age, showing in the elderly a prevalence of ~ 5% in 
the 65–74-year range and of ~ 10% in individuals > 75 years 
old, respectively [31, 38]. Sofi et  al. [39] in evaluating 
dietary habits and lifestyle of Italian subjects, measured 
serum folate in 520 ostensibly healthy subjects, showing 
mean (± SD) values of 5.4 (± 2.6) μg/L. Girelli et  al. [29], 
investigating on the relationship between folate status 
and activity of 5,10-methylenetetrahydrofolate reductase 
(MHTFR) as risk factor for cardiovascular disease (CVD), 
reported similar concentrations in 222 CVD-free controls 
and found ~ 24% of apparently healthy subjects with an 
inadequate folate status on the basis of their MHTFR gen-
otype. This study addressed an additional public health 
problem related to folate status, not considered by CADTH 
but relevant for Caucasian populations: the considerable 
prevalence of MHTFR homozygous mutation (10%–18%) 
and the inverse association between folate concentrations 
in serum and both homocysteine status and CVD risk. 
Although the evidence on the relationship between folate 
status and CVD risk is mild, the correction of hyperho-
mocysteinemia with folic acid supplementation is widely 
used in the general population as well as the combined 
(re)testing of serum folate and plasma homocysteine for 
therapeutic monitoring [40].
In conclusion, in the European region, the adequacy 
of folate status appears to be widely variable across coun-
tries and some populations appear to be characterized by 
a suboptimal folate intake. Lacking robust data, we can 
doubt that the problem of a folate deficiency in the general 
population may be underestimated and neglected.
Tackling the problem by a health technology 
assessment (HTA) approach
As discussed above, for several European countries data 
on folate status in the general population are scarce and 
dated although public health authorities are engaging in 
efforts to increase overall folate intake according to the 
US model, in particular in women of childbearing age for 
the prevention of neural tube defects (NTD) [41, 42]. In a 
recent report, Mastroiacovo and Corchia have observed 
that serum folate concentrations in this women subset 
are comparable to those found in the US female popula-
tion of the same age in the 1988–1994 period before the 
fortification [42]. Notably, these levels are lower than rec-
ommended by the World Health Organization (WHO) and 
far lower than those concentrations minimizing the risk 
for NTD [43]. In the USA, the folate status and changes 
in prevalence of folate deficiency occurring after forti-
fication have been strictly monitored: contemporary to 
a 54.5% increase in folate concentrations, a decrease of 
NTD cases from 10.7 to 7.0/10,000 cases/year after fortifi-
cation has been recorded [43]. A cost-benefit analysis has 
clearly shown that health and economic gains associated 
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to serum folate increase after folic acid fortification far 
outweighed the losses [44]. Indeed, the consequent 
enhanced prevention of myocardial infarction, colorectal 
cancer, NTD, and vitamin B12 deficiency masking resulted 
in a direct positive impact on health outcomes, such as 
annual burden of disease, quality-adjusted life years, and 
costs [44]. Tackling the folate issue by involving key stake-
holders in healthcare policy and decision-making such 
as health management and clinical professions, industry, 
patient organizations, third-party NTD, and government 
has been therefore successful [45].
Firmly rooted in research and in the scientific method, 
HTA aims to support policy makers in making evidence-
informed decisions on the application of scientific knowl-
edge in healthcare and prevention [46]. HTA covers a 
broad range of relevant expertise comprising diagnostic 
and treatment methods, medical equipment, pharma-
ceuticals, rehabilitation and prevention methods, and 
the organizational and supportive systems within which 
healthcare is provided [47]. In agreement with the HTA 
approach, the US National Health and Nutrition Exami-
nation Survey (NHANES) program has involved a multi-
disciplinary panel of 23 experts in folate and vitamin 
assessment, epidemiology, clinical laboratory science, 
and biostatistics. The roundtable also had 10  scientists 
from governmental agencies that conducted and funded 
folate biomarker measurements in NHANES surveys and 
developed relevant reference methods and materials [45]. 
A part from documenting a sharp increase then  followed 
by a slight decrease during the 12-year post- fortification 
period, the roundtable reported on the quality of folate-
related measurement procedures, on the quality of 
 reference procedures and reference materials available 
or under development, as well as provided public health 
considerations for the choice of which folate-related bio-
markers to measure in the population [45]. Accordingly, 
US Health Advisory Committees with respect to European 
counterparts have paid greater attention to the meas-
urement of the actual folate status more than to folate 
intake in the general population, monitoring folate con-
centrations in the US population from pre- (1988–1994) 
to post-fortification (1999–2010) period and estimating 
or predicting the consequent improvement of health out-
comes. Notably, they also focused on the assays available 
for folate testing and on the analytical issues.
Choice of the test for assessing folate status
The available literature is confusing in defining which test 
is more appropriate to assess the adequacy of folate intake 
and status. Even if the measurement of serum folate 
is currently accepted as the test of choice for the clini-
cal assessment of folate status/deficiency, some authors 
have proposed to replace this determination with plasma 
homocysteine or judged more reliable the measurement of 
folate in red blood cells (RBC) [28]. Although its request 
has steeply risen because of the relationship with CVD 
and of a possible correction of its values with synthetic 
folic acid, plasma homocysteine should be considered as 
a non-specific functional indicator of folate status [26]. On 
the other hand, the selection of the sample (serum or RBC) 
where measuring folate may depend on the features of the 
population in relation to the exposure to folic acid fortifi-
cation or supplementation (see below) [48].
Before clarifying the analytical issues related to folate 
determination in serum and RBC, we should retrieve 
information on the various vitamers constituting the 
whole of total folate and their detectability by the avail-
able assays [45]. The predominant form of the vitamin 
naturally found in foods is the tetrahydrofolic (THF) poly-
glutamate, whereas folic acid is the form used in food 
fortification/enrichment and dietary supplement. The 
biologically active THF acid is involved in the synthesis 
of purines, deoxythymidine, and some amino acids. The 
main circulating and stable folate form is the 5-methyl-
tetrahydrofolate (5MeTHF), whereas RBCs predominately 
contain long-chain polyglutamates of 5MeTHF. According 
to isotope dilution–liquid chromatography–tandem mass 
spectrometry (ID-LC-MS/MS) studies, 5MeTHF constitutes 
from 82% to 93% of the total folate found in native serum 
from healthy individuals [49–51]. Additional forms may be 
pteroylglutamic acid (PGA), 5-formyltetrahydrofolic acid 
(5FoTHF), THF, various reduced forms, UMFA, and, pos-
sibly, an intermediate product, the 4-α-hydroxy-5MeTHF 
(hmTHF) [49–51]. The concentration of each form depends 
on factors such as dietary supplementation and food for-
tification [52]. Populations exposed to folic acid fortifica-
tion and known to have a historical prevalence of folic 
acid supplementation are characterized by far higher 
median concentrations of 5MeTHF (~ 17.0 μg/L) and UMFA 
(~ 0.4  μg/L) when compared to subjects from countries 
with no fortification (7.0 and 0.10 μg/L, respectively) [50, 
53]. In addition, for RBC folate, the MTHFR C677T poly-
morphism affects folate vitamers distribution and thus 
the results strictly depend on the genotype [54, 55].
Although there is an increasing interest in detecting 
and quantifying serum folate forms by ID-LC-MS/MS, 
in particular to evaluate the effects of fortification, cur-
rently only information derived from the measurement 
of total folate can be used for the clinical assessment of 
folate status. Thus, considering the wide heterogeneity of 
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forms present in individual biological samples, it is rele-
vant to know what vitamers may be recognized by the mar-
keted assays and enter in the estimate of “total folate”. The 
laboratory measurement of folate is complicated because 
not all forms are characterized by biological activity and 
various inactive degradation products may interfere.
The microbiological assays exclusively enabled the 
evaluation of biologically active folate species, but, 
given the poor performance, they were replaced first in 
NHANES surveys and later in clinical laboratories by 
competitive protein-binding (CPB) measurement proce-
dures, assuring higher repeatability and reproducibility, 
but with some problems of bias [45]. Using the National 
Institute of Standards and Technology (NIST) standard 
reference material (SRM) 1955, the CPB assay by Bio-Rad 
resulted to underestimate total folate concentrations of 
2.6 and 5.8 μg/L by 25% and 40%, respectively, when 
compared to ID-LC-MS/MS assigned values [56]. The 
use of National Institute for Biological Standards and 
Control (NIBSC) 03/178 International Standard revealed 
an underestimation of ~ 10% for CPB Bio-Rad serum 
folate results at an assigned total folate concentration 
of 5.3 μg/L [57]. In general, for the Bio-Rad assay it have 
been reported an under recovery of 5MeTHF and a proper 
folic acid recovery, whereas the estimated recovery of 
other minor folate species was significantly lower or 
higher than expected [45].
With the further development of CPB assays on differ-
ent automated platforms and the availability of External 
Quality Assessment (EQA) data, it became definitively 
evident that various assays bind different folate species 
in the sample with different affinities. The currently avail-
able CPB assays are built on the use of highly specific 
folate-binding proteins (FBP) extracting from the sample 
preferentially 5MeTHF and other vitamers such as folic 
acid and 5FoTHF [58]. The recovery may, however, vary 
according to total folate concentrations present in the 
sample: for instance, the Roche Diagnostics Folate III 
assay, developed according to what ID-LC-MS/MS detects 
[59], measures an average composition of 93.3% 5MeTHF, 
2.3% folic acid, and 4.4% 5FoTHF in serum samples with 
total folate < 22 μg/L, and an average composition of 
81.7% 5MeTHF, 15.7% folic acid and 2.5% 5FoTH for total 
folate concentrations > 22 μg/L (A. Ruschel-Mitscherlich, 
personal communication). CPB assays have also a ten-
dency to over recover PGA and this suggests an increased 
bias in total folate measurements for samples containing 
increased concentrations of PGA. Therefore, CPB assays 
would be more appropriate for the measurement of sera 
with total folate < 22 μg/L, that is to say when used to test 
populations not receiving staple foods fortified with PGA 
[60]. Finally, the affinity of various CPB assays may be 
further affected by slight deviations from the optimal pH 
of 9.3, particularly at the binding phase [61, 62]. Consid-
ering all the described issues, it should not be surprising 
that EQA results for serum folate exhibit a poor inter-
method agreement, particularly at clinically significant 
low concentrations of the analyte [63–65].
The selected calibration regimens may undoubtedly 
contribute to the lack of method comparability. As antici-
pated above, two reference materials for folate became 
available in the last years for implementing traceability 
of the commercial assays. The NIST SRM 1955  has certi-
fied values for 5MeTHF, reference values for folic acid and 
information values for total folate and 5FoTHF. Out of 
three level materials, only the level 2 material (with total 
folate concentration of 5.8 μg/L) provides, however, a reli-
able quality to be used as calibration material being an 
unaltered frozen human serum, whereas commutability 
issues may arise with the use of levels 1 (diluted material) 
and 3 (fortified material) [56]. Importantly, this material 
is currently out of stock and information on a new lot 
release is not available. Being lyophilized, commutabil-
ity could also be an issue for the other reference material, 
the NIBSC 03/178 International Standard (available since 
2007) [57]. Its total folate concentration, determined using 
ID-LC-MS/MS, is 5.33 μg/L, made up of 4.3 μg/L 5MeTHF, 
0.7 μg/L 5FoTHF, and 0.33 μg/L folic acid [57].
The NHANES experts agree on the alternative use of 
serum and RBC folate measures to monitor folate con-
centrations in the US population, warning that the first 
one reflects recent intakes and may be more appropriate 
for the clinical detection of deficiency [45]. On the other 
hand, they suggest that in fortified countries the deter-
mination of RBC folate is preferable, being a sensitive 
and long-term (4  months on average) indicator of folate 
status and stores [45]. Both serum and RBC assays are 
more responsive to interventions with folic acid in sup-
plements and fortified foods than to natural food folates 
(THF polyglutamate), but the increase of serum vs. RBC 
folate concentrations consequent to folic acid fortification 
in the US was far higher (+ 119%–161% vs. + 44%–64%, 
respectively) [66, 67]. In addition, the RBC folate concen-
trations did not show the expected plateau effect if tissue 
saturation occurs at higher intakes [68]. On the other 
hand, RBC folate concentrations fall with vitamin B12 
deficiency, which makes them useful in the evaluation of 
folate effects on vitamin B12 deficient subjects.
A mandatory prerequisite to obtain reliable folate 
results is to prevent the loss of 5MeTHF by promptly pro-
cessing samples according to their stability (2 h at room 
temperature, 48 h at 2–8 °C or freezing at − 70 °C for longer 
Brought to you by | Università degli Studi di Milano
Authenticated
Download Date | 8/9/17 4:56 PM
Ferraro et al.: Serum folate test in European countries and health outcomes      1267
period) [69]. For RBC folate, the in vitro conversion of 
5MeTHF polyglutamates to monoglutamates may further 
complicate the pre-analytical phase [26]. Furthermore, 
for serum folate determination fasting is required as well 
as the rejection of hemolyzed samples [free hemoglobin 
(Hb)  ≥  0.25 g/L].
A final important aspect is the definition of decision 
level for serum folate indicating negative folate balance/
folate deficiency in the evaluated population. Over 
the past three decades, the threshold has been widely 
reviewed, passing from 3.0 to 4.4 μg/L, when the defini-
tion accounted for the relationship with a metabolic indi-
cator (i.e. increase of plasma homocysteine). Although 
the implementation of folate cut-offs had a pivotal role in 
promoting public health interventions gaged on NHANES 
surveys [70–72], the use of decision values could be incon-
sistent and the individual chronic folate deficiency may be 
stochastically found by multiple serial testing. According 
to the estimation of biological variation of folate in serum, 
the far lower within-person variation with respect to the 
inter-individual variation implies a low index of individu-
ality (i.e. ratio of within- to between-subject variances), i.e. 
0.44 [73]. Under this condition, an isolated dichotomized 
interpretation of folate results, resorting to a decision 
limit for deficiency, can be misleading and the longitudi-
nal monitoring of serial folate changes be more effective 
in classifying individuals with relation to their vitamin 
status. This approach is also supported by the number of 
samples needed to theoretically establish an individual’s 
homeostatic set point. According to the current statistical 
approach [74], the number of specimens that should be 
collected to ensure that the mean marker result is within 
± 10% of the individual’s homeostatic set point can be 
obtained according to the following statistics: 1.962 (ana-
lytical CV2 + within-subject biological CV2)/100. Using an 
average analytical CV of 4.0% and an average intra-indi-
vidual CV of 21.5% [73], for folate, it can be estimated that 
each subject should theoretically undergo up to 18 marker 
measurements to achieve a sufficiently accurate estimate 
of the folate individual’s homeostatic set point, which is 
clearly unfeasible.
Status of folate testing in Italy
Inpatients and outpatients
Aiming to characterize the prevalence of folate deficiency 
in the served patient population of our academic metro-
politan hospital, we retrieved a 1-year (April 2015–April 
2016) case series of consecutive serum folate results from 
our laboratory information system. Out of 4225 folate 
values obtained by using Roche Diagnostics Folate III 
assay (code 04476433190) performed on the Modular EVO 
platform, ~ 11.0% were > 20 μg/L, the remaining cases 
exhibiting a median (25th–75th percentile) concentra-
tion of 6.4 (4.8–9.0) μg/L. By selecting results below the 
lower reference limit recommended by the manufacturer 
of our folate assay (4.6 μg/L), 861 (20.4%) results char-
acterized subjects as at risk for folate deficiency. In this 
subset of individuals, the median (25th–75th percen-
tile) folate concentration was 3.8 (3.2–4.2) μg/L. The fre-
quency distributions of serum folate concentrations in 
outpatients [n = 2318; 16.8% < 4.6 μg/L; median (25th–75th 
percentile) 6.8 (5.1–9.4) μg/L, excluding 285 (12.3%) sub-
jects > 20 μg/L] and inpatients [n = 1907; 24.8% < 4.6 μg/L; 
median (25th–75th percentile) 6.0 (4.4–8.4) μg/L, exclud-
ing 181 (9.4%) subjects > 20 μg/L] are reported in Figure 1.
By analyzing folate ordering, we observed that, with 
the exception of patients carrying myelogenous leukemia 
(adding up 9.8% of orders), requests were not preferen-
tially attributable to some specific wards or to specific sets 
of outpatients. In particular, 8.9% and 10.2% of requests 
concerned patients admitted to Departments of Internal 
Medicine and Infectious Disease, while the number of 
requests coming from other divisions was lower [Neu-
rology and Stroke Unit (7.6%), Nephrology and Dialysis 
(4.6%), and Gastroenterology (3.5%)]. More than half 
of the total results below the lower reference limit were 
partitioned among the Department of Internal Medicine 
(25.3%), the Department of Infectious Disease (15.4%), 
and general outpatients (18.1%). Neurology and Stroke 
Unit (8.7%), Nursing Home Care (7.1%), Outpatients carry-
ing Myelogenous Leukemia (5.7%), Nephrology and Dialy-
sis (4.1%), Gastroenterology (3.7%), Reumatology (2.1%), 
and Oncology (1.6%) showed a lower prevalence of serum 
folate reduction.
Considering folate retesting, we found 732 results from 
337 retested patients (62.4% outpatients). Each patient 
had a mean (SD) of 2.2 (0.4) requests/year, in 14.2% of 
patients, the folate tests being  ≥  3. The average (SD) time 
interval of retesting was 3.4 (2.5) months between the first 
two requests and 3.1 (2.0) months between the second 
and the third one. Figure 2 displays the frequency distri-
bution of absolute and percentage changes between the 
first two serial measurements of serum folate in retested 
subjects. Accounting for an average intra-individual CV 
of 21.5% [73] and the analytical CV of the assay, one can 
derive the reference change value (RCV) for serum folate. 
The RCV is defined as the change needed between two 
serial results from the same individual to be significantly 
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different, beyond the measurement error and the bio-
logical variability of the analyte [74]. In particular, at the 
average analytical CV for our assay of 4.0% (data from 
2015 fiscal year internal quality control), the derived RCV 
for serum folate is 60.6%. By applying it to our popula-
tion, we can identify a subgroups of 43 subjects (12.8% of 
retested patients) with a positive change > 60.6% between 
the two serial tests, likely related to a recently started 
folic acid supplementation, and another group of 32 indi-
viduals (10.4%) with a decrease in serum folate > RCV, in 
whom an actual folate deficit was conceivable (Figure 2). 
Interestingly, only 12 subjects in the latter group had the 
second value < 4.6 μg/L, suggesting a possible underesti-
mation of vitamin deficiency if the evaluation is resorting 
to a fixed cut-off. Furthermore, 14 individuals from this 
subgroup showed a baseline value > 14 μg/L indicating 
a recently interrupted supplementation. It is noteworthy 
that folate body stores generally represent a 2–3 months 
supply, and after stopping supplementation, folate defi-
ciency may suddenly occur for an inadequate intake or 
increased requirement for the vitamin [75]. The remaining 
262 retested subjects displaying a change < 60.6% between 
two measurements (i.e. a stable trend of folate values) 
could be in turn divided into three subsets, the first with 
folate values stably  ≥  14 μg/L, indicating an ongoing sup-
plementation, the second with baseline values inside the 
reference interval and the third with baseline folate con-
centrations < 4.6 μg/L. In the first and the third subsets, 
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Figure 1: Frequency distributions of serum folate results in outpatients (n = 2318) and inpatients (n = 1907) retrieved from 1-year consecutive 
case series in the population served by the authors’ laboratory.
Vertical dashed lines indicate the lower reference limit (4.6 μg/L) recommended by the manufacturer of folate assay (Roche Diagnostics 
Folate III, code 04476433190).
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Figure 2: Frequency distribution of absolute and percentage changes between the first two serial measurements of serum folate in retested 
subjects (n = 337) from the surveyed population.
RCV, reference change value.
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the retesting was not justified. Figure 3 displays typical 
patterns of folate change found in retested subjects.
Healthy population
We also retrieved data from a continuous case series of 538 
blood donors [men, 58.4%; median (25th–75th percentile) 
age, 36 (25–45) years, 11.3% non-Italian] routinely tested 
for serum folate (Roche Folate III assay, code 04476433190). 
Among these subjects, three had concentrations > 20 
μg/L, and the remaining 535, a median concentration of 
6.0 μg/L, with 2.5th and 97.5th percentile limits at 3.3 and 
13.9 μg/L, respectively. Figure 4 reports the frequency dis-
tribution. There was no correlation between serum folate 
and blood Hb concentrations and between folate and 
the mean corpuscular volume of erythrocytes in these 
subjects. Interestingly, 100 (18.6%) of these apparently 
healthy individuals were below the assay manufacturer’s 
declared lower reference limit (4.6 μg/L) that was appar-
ently too high for our population. On the other hand, by 
defining the adequate status of folate according to Dho-
nukshe-Rutten et  al. [28] as serum concentrations > 6.6 
μg/L, we observed that only 40.7% of subjects seemed 
to have an adequate folate intake from diet. A significant 
increase (p < 0.01) of folate concentrations in serum was 
shown with age increase, in female gender, and in non-
Italian individuals.
Appropriateness of test request
In agreement with previous reporting claiming an 
overuse/misuse of serum folate testing [1, 4], we con-
firmed an excess of test requests in our institution quite 
equally distributed between different population subsets 
and often consistent with screening purposes. Further-
more, according to our data, the proportion of subjects 
undergoing folate testing during or just after vitamin sup-
plementation seems to be quite relevant, even if testing 
folate in these patients is probably useless for some con-
solidated reasons:
(a) except for patients with pernicious anemia, an intake 
of synthetic folic acid is unlikely to be associated with 
adverse events [21];
(b) there are no data assuring that the available assays 
can reliably detect serum folate absolute concentra-
tions related to the maximum tolerable intake level 
of folic acid (i.e. 5 mg/day in the general population 
or 1 mg/day in the elderly and in patients with perni-
cious anemia) [21];
(c) serum folate concentrations may rapidly fall down 
after discontinuing the assumption [76].
The data by Hao et  al. [76] support the doubts on the 
effectiveness of monitoring folic acid supplementa-
tion. These authors showed that in healthy women, the 
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Figure 3: Typical patterns of serum folate change in retested sub-
jects. The average (SD) time of retesting was 3.4 (2.5) months.
(A) Subject with a positive change higher than the reference change 
value (RCV) (60.6%), likely related to a recently started folic acid 
supplementation; (B) subject with a decrease in serum folate > RCV, 
in whom an actual folate deficit is conceivable; (C) subject with 
a decrease in serum folate > RCV and a baseline value > 14 μg/L, 
indicating a recently interrupted supplementation; (D) subject with 
folate values stably  ≥  14 μg/L, indicating an ongoing supplementa-
tion; (E) subject with baseline value inside the reference interval and 
change lower than RCV, indicating a unchanged lifestyle; (F) subject 
with folate concentrations lower than the lower reference limit, 
indicating a possible folate deficiency.
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Figure 4: Frequency distribution of folate concentrations in serum 
of 538 healthy blood donors.
Arrows indicate the 2.5th (3.3 μg/L) and the 97.5th (13.9 μg/L) per-
centile of value distribution.
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supplementation with 0.4  mg/day corresponds to circu-
lating folate concentrations of approximately 16 μg/L, 
measured 3  months after starting (‘plateau level’). No 
further increase is recorded at 6 months, whereas a rapid 
decrease (− 55% in average) occurs 3  months after dis-
continuing supplementation. For higher folic acid doses 
(i.e. 4 mg/day, which is close to the tolerable upper intake 
level), serum folate concentrations amounted to 24 μg/L 
after the first 3 months and showed a far sudden decrease 
(− 66%) after cessation [76].
In agreement with these experimental data, we can 
argue that there is no suitable cost-effectiveness in moni-
toring the vitamin supplementation by folate testing. 
Furthermore, considering that the folic acid intake is no 
harmful in the general population and only patients with 
pernicious anemia may be potentially affected if supple-
mented with > 1 mg/day (corresponding to a serum plateau 
level of ~ 20 μg/L), the dilution of samples with folate 
concentrations > 20 μg/L (i.e. the upper calibration limit 
for several assays), once the test is executed, to provide 
definite concentrations within 40 μg/L (corresponding to 
the highest folic acid intake) is also not cost-effective. On 
the other hand, it is proved that, by discontinuing intake, 
folate retesting is useless to evaluate the actual correction 
of the deficit [77].
In summary, the serum folate test is inappropriately 
ordered when
(a) there is no specific risk condition/suspicion for folate 
deficiency/inadequate status (Table 1);
(b) the subject is undergoing or has recently undergone 
folic acid supplementation;
(c) retesting at 3–6 months to evaluate the actual correc-
tion of the deficit after intake discontinuation.
By applying these recommendations on the current folate 
testing strategy applied in our institution, we can estimate 
a ~ 50% saving in laboratory costs.
Estimating folate deficiency and 
need to predict the effect of assay 
recalibration
In the general population, serum folate testing is fre-
quently used to screen for vitamin deficiency. In our expe-
rience, ~ 94% of requests are indeed associated to those 
for vitamin B12 testing. According to our data, the preva-
lence of subjects exhibiting folate concentrations below 
the lower reference limit is actually remarkable in any 
evaluated setting (inpatients, ~ 25%; outpatients, ~ 17%; 
healthy subjects, 18.6%), always quite far from estimates 
in fortified countries [6]. How this frequency is directly 
connected with the prevalence of folate deficiency and 
how much it is conversely dependent from the correctness 
of cut-off establishment and its usefulness and from accu-
racy of folate assays is, however, unknown.
It has long been known that the actual prevalence of 
folate deficiency in the population may significantly shift 
with the reformulation of assays [78]. This is troublesome 
when monitoring over time trends in folate concentration 
distributions to promote public health intervention and 
policies on the population [26, 63, 64]. To improve harmo-
nization of assays, some commercial folate methods have 
recently undergone recalibration to the NIBSC 03/178 Inter-
national Standard in order to fulfil the European Union 
Directive on in vitro diagnostic medical devices that asks 
diagnostic manufacturers to ensure traceability of their 
analytical systems to recognized higher-order references 
[79]. However, tracing back the calibration of commercial 
assays to a new reference material can modify results and 
actually alter their relation to existing reference intervals 
and decision limits, invalidating the clinical decision-
making criteria currently used [80–82]. In fact, we have 
recently experienced this problem when Roche Diagnos-
tics has replaced the Folate III assay code 04476433190 
(which was home-made calibrated) by the Folate III assay 
code 07559992190 (traceable to NIBSC 03/178  material). 
After the kit replacement, we immediately recorded a sig-
nificant change in the average folate value measured on 
a fresh-frozen serum pool used daily to check the long-
term assay imprecision, with a mean underestimation of 
28.8% of total folate when measured by the new version 
of the assay (6.6 vs. 4.7 μg/L, respectively). We confirmed 
the effect of assay recalibration in providing lower folate 
results by a preliminary comparison study on 15 clinical 
samples, aliquoted and stored at − 80 °C, measured by 
each assay. Comparing the previous with the new assay, 
the mean (± SD) folate concentrations resulted 6.6 (± 0.5) 
vs. 4.7 (± 0.4) μg/L, respectively (average bias, − 28.8%). A 
stronger proof was finally derived from the regional EQA 
program where, by cumulating interlaboratory data gen-
erated by participants using the Roche assay, a dichoto-
mous distribution of total folate results became evident. 
After partitioning data for assay code, the obtained mean 
(± SD) for laboratories using code 04476433190 assay 
(n = 6) was 4.0 (± 0.4) μg/L vs. 2.0 (± 0.5) μg/L for code 
07559992190 laboratories (n = 30) [data from EQA exercise 
no. 4/2016]. Thus, we can speculate that at a folate concen-
tration around the lower reference limit of the old assay, a 
positive bias of 50% vs. the new assay can be observed.
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Given this large variation in folate results, it is very rel-
evant to predict the impact due to the introduction of the 
recalibrated assay on the prevalence of folate deficiency 
with respect to the previous generation assay. In the 
modified package insert, the assay manufacturer is rec-
ommending a new lower reference limit (3.9 μg/L) for the 
interpretation of serum folate results in European popula-
tions. Taking into account the ~ 50% between-assay differ-
ence experimentally found at this concentration level, the 
shift from 4.6 μg/L (old calibration) to 3.9 μg/L (new cali-
bration assay) appears, however, to be inconsistent. Con-
sequently, a misleading overestimate of the prevalence 
of folate deficiency is expected if the recalibrated Roche 
assay will be used together the manufacturer’s newly rec-
ommended lower reference limit. New experimental data 
from healthy blood donors (similar to those presented in 
Figure 4 for the former assay) have, therefore, to be quickly 
obtained with the recalibrated assay in order to accurately 
define the reference distribution in the proper population 
and derive decisional strategies for folic acid supplemen-
tation. This might also require the (re)formulation of safe 
and effective health policies that are patient-focused and 
seek to achieve the best outcome.
Concluding remarks
Today, the evaluation of folate status and intake still 
represents an important aspect that healthcare systems 
of several European countries have to deal with. Several 
surveys have reported that the folate intake and status in 
most European countries are suboptimal to ensure physi-
ologic growth and fetal development and maintenance 
of optimal health [28]. Considering the poor stability and 
incomplete bioavailability of natural food folates when 
compared to the synthetic form, approaches to optimize 
vitamin intake and improve health population outcomes, 
in particular focusing on the NTD risk reduction, have to 
be considered [41, 42, 72]. Some authors agree with the 
introduction of mandatory fortification following the 
US and Canada policies, while others boost for the sup-
plementation with folic acid capsules of groups at risk 
(i.e. elderly and women of childbearing age) [83, 84]. 
In general, in policy decisions, Europe shows a greater 
caution than North America region, dictated by the safety 
issues of folic acid supplementation/fortification [32, 85]. 
Concerns have been raised about the potential adverse 
effects of high circulating concentrations of folic acid and 
of traces of UMFA, the latter not reliably detectable by 
clinical assays [86–88]. Finally, the information derived 
from the recent medical literature showing no decrease in 
the incidence of NTD in Europe [89] should be considered 
in promoting or not supplementation strategies.
The ability to develop regional or national consen-
sus strategies on populations at risk and to promote 
evidence-based health policy-making are contingent on 
having reliable data and this cannot disregard the knowl-
edge of biomarkers of folate status and of related assays 
[25]. Reviews by multidisciplinary panel of authoritative 
experts have focused on the pre-analytical, analytical, and 
post-analytical issues related to the biomarkers of folate 
status, clarifying that the choice of the method (serum or 
RBC folate) depends on the features of the investigated 
population (prevalence of deficiency, spread of fortified 
staple food) and on the outcome (assessment of the indi-
vidual folate status/risk for deficiency or characterization 
of the population intake/status) [6, 26, 28, 90]. For surveys 
on the general population, the measurement of serum 
folate may not be a reliable method, but it becomes the 
test of choice for the clinical use and the assessment of 
individual deficiency [26]. Fulfilling recommendations on 
the pre-analytical management of samples is mandatory to 
obtain reliable results, but it is their interpretation that is 
central for identifying individual risk for folate deficiency. 
In addition to the limited usefulness of a cut-off value (i.e. 
the lower reference limit) due to the wide inter-individual 
biological variability of folate, we can doubt on the reli-
ability of the reference intervals reported by assay manu-
facturers and recommended for European populations 
[28, 73]. As across European countries, the voluntary and 
liberal fortification policies are greatly heterogeneous, 
the estimation of reference intervals is likely to be con-
ditioned by the possible inclusion in the reference group 
of subjects consuming fortified staple foodstuffs [28, 37]. 
Furthermore, results obtained by investigating and com-
paring folate intake across populations have suggested 
shifting the outcome from detecting folate deficiency to 
assessing folate status at the individual level. As reported 
by Bailey et al. [91], meeting a criterion for assessing indi-
vidual folate deficiency (or its prevalence in a population) 
is not synonymous of optimal folate status also in the “not 
deficient” portion of the population [91]. In several set-
tings, although an out-and-out folate deficiency may be 
rare, a suboptimal folate status impairing health condi-
tions may be more common and, for this reason, the test 
ordering should be appropriately addressed.
A cost-effective use of folate testing in the clini-
cal setting implies the knowledge of (a) what biomarker 
order, (b) what population investigate, and (c) when or 
if retest. All main documents agree on the use of serum 
folate testing without adding homocysteine test when the 
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outcome is to evaluate the individual risk of folate defi-
ciency/status [6, 26]. In countries undergoing mandatory 
fortification, the population exhibits a distribution of cir-
culating folate vitamers different from European countries 
and the prevalence of deficiency in the general population 
is far lower [52]. Accordingly, in fortified populations the 
test request should be restricted to some groups at risk, 
but not recommended in both inpatients and outpatients 
[5]. In European countries, particularly in those not adopt-
ing national fortification policies, these recommendations 
should be cautionary considered, since there is a sounded 
evidence of a suboptimal folate intake in the general 
population. Our local data further show a considerable 
prevalence of risk for deficiency in all tested populations 
(outpatients, inpatients, and blood donors) and suggest 
that in all these subsets folate testing may be ordered 
according to the individual risk and to the suspect for 
an inadequate intake, possibly requiring correction with 
folic acid supplementation or simply a change in dietary 
habits. We should remind that several European National 
Institutes of Health are working to promote the imple-
mentation of healthcare policies to enhance the general 
availability of fortified foods with the final aim to prevent 
in the population the increase of clinical conditions and 
genetic defects linked to an impaired folate status [42, 
92–94]. Starting from 2005, the National Health System in 
Italy enables healthcare providers to prescribe folic acid 
supplements without any charge to all women of child-
bearing age (the cost to the National Health System of a 
box containing 28 pills of 400 μg folic acid is ~ 2 €) [41]. 
Facing on data on the prevalence of folate deficiency, the 
need for a possible extension of this policy to other groups 
at risk (e.g. the elderly) may be considered. Finally, we 
should remind that it is useless to measure and monitor by 
retesting serum folate in individuals undergoing supple-
mentation, since this cannot warrant a long-term supply 
(> 3 months) (examples C and D in Figure 3) [75, 76]. Fur-
thermore, repeating folate measurement is also useless 
in individuals with strongly suspected folate deficiency 
(example F in Figure 3) [77].
In conclusion, with respect to fortified countries, in 
European populations, there is evidence on the need and 
relevance to perform serum folate testing without specific 
restrictions. According to the data analysis, it is, however, 
mandatory to boost for more appropriate requests to curb 
the excess of costs linked to the spreading of folate testing. 
We should emphasize that the effectiveness of the test is 
maximized when oriented to subjects suggestive or at 
risk for deficiency and low or absent when used as tool 
for screening or serial monitoring of vitamin intake or 
supplementation. In the latter case, to prevent retesting, 
a computer-based-limiting management strategy may 
be considered [95]. Finally, we should be aware that the 
recent recalibration of several commercial assays in view 
of harmonization policies is likely significantly shifting 
results and, if not correctly managed, potentially affect-
ing the detection of folate deficiency in individuals at risk.
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